Details for New Drug Application (NDA): 020229
✉ Email this page to a colleague
The generic ingredient in LEUSTATIN is cladribine. There are eight drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the cladribine profile page.
Summary for 020229
Tradename: | LEUSTATIN |
Applicant: | Janssen Pharms |
Ingredient: | cladribine |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 020229
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Feb 26, 1993 | TE: | RLD: | Yes |
Complete Access Available with Subscription